tweenvest

Parabilis Medicines, Inc. (NasdaqGS: PBLS)

Health Care · Biotechnology · US

$28.45

+0.07% today · -10.0% 1Y

Public summary
A free snapshot of Parabilis Medicines, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Parabilis Medicines, Inc. (NasdaqGS: PBLS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.56B and employs 145 people.

Over the last twelve months the share price has lost 10.0%, trading between 22.66 and 42.49.

Tweenvest scores Parabilis Medicines, Inc. across four factors: quality 12/100, value 100/100. Its strongest factor is value.

PBLS price history

Jun 12, 2026 · 27.26Weekly closes 22.75 – 41.73Nov 16, 2026 · 28.45

Key figures

Market cap
$3.56B
Revenue (TTM)
$2.26M
P/E
-20.90
EPS
-22.78
Dividend yield
—
Beta (5Y)
—
52-week high
$42.49
52-week low
$22.66
Avg volume (3M)
—
Shares outstanding
125.26M
Employees
145
Next earnings
—

About Parabilis Medicines, Inc.

Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

ISIN
US6989551014
Founded
2015
Listed since
Jun 10, 2026
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
Disc Medicine, Inc.NasdaqGM: IRON$3.79B$83.23-4.42%
SELLAS Life Sciences Group, Inc.NasdaqCM: SLS$3.66B$14.86-17.21%
Relay Therapeutics, Inc.NasdaqGM: RLAY$3.65B$16.51+0.24%
Arcutis Biotherapeutics, Inc.NasdaqGS: ARQT$3.57B$28.26+2.65%
Beijing Tiantan Biological Products Co., Ltd.SHSE: 600161$3.56BCN¥12.01-1.72%
Iovance Biotherapeutics, Inc.NasdaqGM: IOVA$3.46B$7.31-2.27%
Viridian Therapeutics, Inc.NasdaqCM: VRDN$3.42B$30.12+0.20%
Suzhou Zelgen Biopharmaceuticals Co., Ltd.SHSE: 688266$3.37BCN¥85.05-2.92%

Browse every Biotechnology company →